EDMA

EDMA
Clinical data
Routes of; administration	Oral
ATC code	none;
Legal status
Legal status	CA: Schedule III; DE: NpSG (Industrial and scientific use only); UK: Class B;
Identifiers
	IUPAC name 1-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-methylpropan-2-amine;
CAS Number	133787-66-3 ;
PubChem CID	24257269;
ChemSpider	23553090 ;
UNII	UJ7UU2C6E6;
CompTox Dashboard (EPA)	DTXSID501027143 ;
Chemical and physical data
Formula	C12H17NO2
Molar mass	207.273 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(Cc1ccc2c(c1)OCCO2)NC;
	InChI InChI=1S/C12H17NO2/c1-9(13-2)7-10-3-4-11-12(8-10)15-6-5-14-11/h3-4,8-9,13H,5-7H2,1-2H3 ; Key:UJKWLAZYSLJTKA-UHFFFAOYSA-N ;
	(verify)

3,4-Ethylenedioxy-N-methylamphetamine (EDMA) is an entactogen drug of the methamphetamine class. It is an analogue of MDMA where the methylenedioxy ring has been replaced by an ethylenedioxy ring. EDMA was first synthesized by Alexander Shulgin. In his book PiHKAL, the dosage is listed as 150–250 mg, and the duration listed as 3–5 hours. According to Shulgin, EDMA produces a bare threshold consisting of paresthesia, nystagmus, and hypnogogic imagery, with few to no other effects. Scientific research has demonstrated that EDMA acts as a non-neurotoxic serotonin releasing agent with moderately diminished potency relative to MDMA, and with negligible effects on dopamine release.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.